Academic Journal
Q1The Lancet Haematology
About The Lancet Haematology
The Lancet Haematology is a scholarly journal published by Elsevier Ltd. SCImago 2025 lists it in Q1, with an SJR of 6.899 and H-index of 113.
Coverage: 2014-2026. Research categories: Hematology (Q1).
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope information will be added after verification.
Recent Research Articles
Latest publications matched automatically by ISSN.
Living with a bleeding disorder as a woman
Alexandra Robledo
2026-09 · DOI: 10.1016/s2352-3026(26)00150-xFAIR(er) treatment of non-anaemic iron deficiency during pregnancy: clarifying the evidence – Authors' reply
Naomi Cano-Ibáñez, Tayyiba Wasim, Natasha Bushra, Javier Zamora et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00200-0Concurrent BCR::ABL1 and CBFA2T3::GLIS2 fusions in an adult patient with acute leukaemia
Jiayu Huang, Ting Wu, Hongming Zhu, Jianfeng Li et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00105-5Menstruation in Nepal: tradition, stigma, and transition
Anshumala Joshi, Amrita Giri
2026-09 · DOI: 10.1016/s2352-3026(26)00138-9Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party
Imke E Karsten, Norbert Schmitz, Mathilde Fekom, Laurence de Leval et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00147-xISTH 2026 Congress
Lan-Lan Smith, Emma Cookson
2026-09 · DOI: 10.1016/s2352-3026(26)00225-5High time for risk-adapted treatment in mantle cell lymphoma
Ingrid Glimelius, Anna Nikkarinen, Leo Meriranta, Simon Husby et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00127-4Building stronger blood systems
Talha Burki
2026-09 · DOI: 10.1016/s2352-3026(26)00220-6Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial
Jeremy S Abramson, Susan Geyer, Sharmila Giri, Levi Pederson et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00191-2Beyond maximum grade: a decade in the making
The Lancet Haematology
2026-09 · DOI: 10.1016/s2352-3026(26)00226-7CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study
Marie José Kersten, Maria T Kuipers, Pim G N J Mutsaers, Evelyne Willems et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00192-4Beyond maximum grade: key regulatory considerations in adverse event reporting
Kyriaki Tzogani, Tarec C El-Galaly, Neil Everest, Christian Gisselbrecht et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00168-7Reproductive health in Ireland: moving forward as others roll back
Dearbhla Doherty, Michelle Lavin
2026-09 · DOI: 10.1016/s2352-3026(26)00148-1Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies
Tove Wästerlid, Bryan S Valcarcel, Diana Presno, German Stemmelin et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00113-4Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers
Tarec Christoffer El-Galaly, Irène Buvat, Raul Córdoba, Matteo G Della Porta et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00126-2Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial
Lorenzo Falchi, Joost S P Vermaat, Joshua D Brody, Lori Leslie et al.
2026-09 · DOI: 10.1016/s2352-3026(26)00198-5Beyond maximum grade: making toxicity count
Guanqiao Li, Michelle L Hermiston
2026-09 · DOI: 10.1016/s2352-3026(26)00199-7Sex and gender inequality in classical haematology: time to act
The Lancet Haematology
2026-08 · DOI: 10.1016/s2352-3026(26)00172-9Redefining plasma cell leukaemia
S Vincent Rajkumar, Shaji Kumar
2026-08 · DOI: 10.1016/s2352-3026(26)00131-6Between rules and reality
Josephine Kievit
2026-08 · DOI: 10.1016/s2352-3026(26)00140-7Reviews
Community Reviews
Version History
September 8, 2026 at 7:40 am
September 8, 2026